文献速递急性肾损伤遗传性与小管间质肾病

m7G甲基转移酶METTL1通过破坏线粒体功能促进急性肾脏炎症

The m7G methyltransferase METTL1 promotes acute kidney inflammation by disrupting mitochondrial function.
PubMed 文献 · Kidney Int · 2025-12-15

该研究探讨了METTL1介导的m7G修饰在急性肾损伤(AKI)中的作用。通过肾小管上皮细胞特异性METTL1敲除小鼠及多种AKI模型,发现METTL1缺失减轻肾损伤和炎症;机制上METTL1通过Quaking稳定TEAD2 mRNA,TEAD2转录抑制ACADM损害线粒体功能,放大促炎反应;靶向METTL1可缓解小鼠AKI。

要点

  • METTL1介导的m7G修饰在AKI患者和小鼠肾小管上皮细胞中显著上调。
  • 肾小管上皮细胞特异性敲除METTL1减轻多种AKI模型的肾损伤和炎症。
  • 靶向METTL1/TEAD2/ACADM轴或可治疗炎症性肾脏病。

核心结论

  • 靶向METTL1/TEAD2/ACADM轴可能是炎症性肾脏病的潜在治疗策略。

研究设计与样本

  • 使用肾小管上皮细胞特异性METTL1条件性敲除小鼠,在顺铂、缺血再灌注和盲肠结扎穿刺三种AKI模型中评估功能。
  • 获取AKI患者肾组织及肾癌患者非肿瘤肾组织,进行RNA测序和m7G甲基化RNA免疫沉淀测序。

主要发现

  • AKI患者和小鼠肾小管上皮细胞中m7G修饰和METTL1表达均显著上调。
  • 肾小管上皮细胞特异性敲除METTL1显著减轻多种AKI小鼠模型的肾损伤和炎症。
  • METTL1介导的m7G修饰通过结合蛋白Quaking增强TEAD2 mRNA稳定性。
  • 升高的TEAD2通过转录抑制ACADM损害线粒体功能,从而放大促炎反应。
  • 四面体框架DNA纳米结构介导的METTL1敲低及METTL1抑制剂AZD1080在预防和治疗方式下均有效减轻小鼠AKI严重程度。

临床怎么用

  • METTL1/TEAD2/ACADM轴可作为炎症性肾脏病的潜在治疗靶点。
  • METTL1抑制剂AZD1080或DNA纳米结构介导的METTL1敲低在动物模型中显示预防和治疗AKI的效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: RNA modifications regulate the progression of inflammatory diseases. However, the role of N7-methylguanosine (m7G) modification and its regulatory enzyme, methyltransferase-like 1 (METTL1), in inflammatory kidney diseases remains poorly understood. Here, we aimed to investigate the function and underlying mechanisms of METTL1-mediated m7G modification in acute kidney injury (AKI). METHODS: Kidney tubular epithelial cell (TEC)-specific METTL1 conditional knockout mice were used to evaluate the functional role of METTL1 in multiple AKI mouse models (cisplatin, ischemia/reperfusion and cecal ligation/puncture). Additionally, kidney tissue was obtained from patients with AKI and from the non-tumor kidney tissue of patients with nephrectomy for kidney cancer. RNA sequencing and m7G-methylated RNA immunoprecipitation sequencing were performed to identify downstream targets and elucidate underlying mechanisms. RESULTS: Both m7G modification and METTL1 expression were markedly upregulated in TECs from patients and mice with AKI. TEC-specific deletion of METTL1 significantly attenuated kidney injury and inflammation in the multiple AKI mouse models. Mechanistically, METTL1-mediated m7G modification enhanced the stability of the TEA domain transcription factor 2 (TEAD2) mRNA by the binding protein Quaking. Elevated TEAD2 impaired mitochondrial function by transcriptionally repressing medium-chain acyl-CoA dehydrogenase (ACADM), thereby amplifying proinflammatory responses. METTL1 knockdown mediated by tetrahedral framework DNA nanostructures, as well as pharmacological inhibition with AZD1080, a novel METTL1 inhibitor, effectively alleviated the severity of AKI in mice in prevention and therapeutic approaches. CONCLUSIONS: Our findings suggest that targeting the METTL1/TEAD2/ACADM axis may represent a potential therapeutic strategy for inflammatory kidney diseases.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Xie SS, Dong YH, Gao J, et al. The m7G methyltransferase METTL1 promotes acute kidney inflammation by disrupting mitochondrial function. Kidney Int. 2025. PMID: 41407011. doi:10.1016/j.kint.2025.11.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。